Literature DB >> 10523865

Molecular cloning and characterization of the 5' region of the mouse trkA proto-oncogene.

M P Sacristán1, J G de Diego, M Bonilla, D Martín-Zanca.   

Abstract

The trkA proto-oncogene encodes a high-affinity NGF receptor that is essential for the survival, differentiation and maintenance of many neural and non-neural cell types. Altered expression of the trkA gene or trkA receptor malfunction have been implicated in neurodegeneration, tumor progression and oncogenesis. We have cloned and characterized the 5' region of the mouse trkA gene and have identified its promoter. trkA promoter sequences are GC-rich, lack genuine TATA or CAAT boxes, and are contained within a CpG island which extends over the entire first coding exon. The mouse trkA transcription start site is located 70/71 bp upstream to the AUG translation initiation codon. Sequence analysis showed that the gene encoding the insulin receptor-related receptor, IRR, is located just 1.6 kbp upstream to the trkA gene and is transcribed in the opposite direction. We have used trkA-CAT transcriptional fusions to study trkA promoter function in transient transfection experiments. RNase protection assays and CAT protein ELISA analyses showed that a 150 bp long DNA segment, immediately upstream to the start site, is sufficient to direct accurate transcription in trkA-expressing cells. Dissection of this fragment allowed us to identify a 13 bp cis-regulatory element essential for both promoter activity and cell-type specific expression. Deletion of this 13 bp segment as well as modification of its sequence by site-directed mutagenesis led to a dramatic decline in promoter activity. Gel mobility shift assays carried out with double-stranded oligonucleotides containing the 13 bp element revealed several specific DNA-protein complexes when nuclear extracts from trkA-expressing cells were used. Supershift experiments showed that the Sp1 transcription factor was a component of one of these complexes. Our results identify a minimal trkA gene promoter, located very close to the transcription start site, and define a 13 bp enhancer within this promoter sequence.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10523865     DOI: 10.1038/sj.onc.1202963

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  6 in total

1.  Molecular basis for keratoconus: lack of TrkA expression and its transcriptional repression by Sp3.

Authors:  Alessandro Lambiase; Daniela Merlo; Cristiana Mollinari; Paolo Bonini; Anna Maria Rinaldi; Mauro D' Amato; Alessandra Micera; Marco Coassin; Paolo Rama; Stefano Bonini; Enrico Garaci
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-07       Impact factor: 11.205

2.  Bex3 Dimerization Regulates NGF-Dependent Neuronal Survival and Differentiation by Enhancing trkA Gene Transcription.

Authors:  Laura Calvo; Begoña Anta; Saray López-Benito; Carlos Martín-Rodriguez; Francis S Lee; Pilar Pérez; Dionisio Martín-Zanca; Juan C Arévalo
Journal:  J Neurosci       Date:  2015-05-06       Impact factor: 6.167

3.  Species-specific organization of CpG island promoters at mammalian homologous genes.

Authors:  M Cuadrado; M Sacristán; F Antequera
Journal:  EMBO Rep       Date:  2001-07-03       Impact factor: 8.807

4.  Interaction of Huntington disease protein with transcriptional activator Sp1.

Authors:  Shi-Hua Li; Anna L Cheng; Hui Zhou; Suzanne Lam; Manjula Rao; He Li; Xiao-Jiang Li
Journal:  Mol Cell Biol       Date:  2002-03       Impact factor: 4.272

5.  Transcriptional dysregulation of TrkA associates with neurodegeneration in spinocerebellar ataxia type 17.

Authors:  Anjali G Shah; Meyer J Friedman; Shanshan Huang; Meredith Roberts; Xiao-Jiang Li; Shihua Li
Journal:  Hum Mol Genet       Date:  2009-07-30       Impact factor: 6.150

6.  Targeted viral vector transduction of relaxin-3 neurons in the rat nucleus incertus using a novel cell-type specific promoter.

Authors:  Alexander D Wykes; Sherie Ma; Ross A D Bathgate; Andrew L Gundlach
Journal:  IBRO Rep       Date:  2019-12-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.